Tiny biotech stock, big 14.2% yield
This small-cap gem with a monster dividend focuses on 'humanization' of antibodies and releated patents
Focusing on dividends sometimes attracts the scorn of active traders who think this is a slow and boring way to make money on Wall Street. But not all dividend payers are stuffy blue chips that track the major indexes.
In fact, there are some really great small-cap stocks out there that provide mammoth dividend yields on top of upside potential in shares.
Some common places to find small-cap stocks with monster yields are in the REIT industry or with publicly traded hedge funds ... but one little biotech stock with a monster yield of 14.2% proves big dividends can come in unlikely places.
PDL BioPharma (PDLI) is a delightful exception to conventional thinking about dividend stocks. The company engages in the management of "antibody humanization patents" as well as royalty assets and license agreements with various biotechnology and pharmaceutical firms. In a nutshell, the process of "humanization" helps makes medications compatible with the biology of men and women so that they work properly.
So how can a company like this burn so much cash in dividend payouts when the cost of drug research and approval is so steep?
Well, the thing about PDL Biopharma is that it doesn't do much research at all. It receives royalties based on these license agreements on sales of a number of humanized antibody products marketed today, and also might receive royalty payments on additional humanized antibody products launched before its patent expire between 2013 and 2014.
That means PDL is a cash-rich intermediary for patents, and has plenty of cash to pay some monster dividends.
Obviously, the downside is that if someone comes up with another way to humanize antibodies and provide that technology to Big Pharma in the next few years, PDLI's run is over. But on the other hand if drugmakers continue to rely on PDL Biopharma's patents for their medications, it will only boost the company's revenue stream.
Copyright © 2013 Microsoft. All rights reserved.
Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.
The offering could become the second-biggest this year if underwriters exercise an option to buy more shares.
VIDEO ON MSN MONEY
Top Stocks provides analysis about the most noteworthy stocks in the market each day, combining some of the best content from around the MSN Money site and the rest of the Web.
Contributors include professional investors and journalists affiliated with MSN Money.
Follow us on Twitter @topstocksmsn.